Labcorp Holdings Beheer

Beheer criteriumcontroles 3/4

De CEO Labcorp Holdings is Adam Schechter, benoemd in Nov2019, heeft een ambtstermijn van 11.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.98M, bestaande uit 8.6% salaris en 91.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.1% van de aandelen van het bedrijf, ter waarde MX$ 429.23M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 9.7 jaar.

Belangrijke informatie

Adam Schechter

Algemeen directeur

US$16.0m

Totale compensatie

Percentage CEO-salaris	8.6%
Dienstverband CEO	5yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	9.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Adam Schechter's beloning veranderd ten opzichte van Labcorp Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$436m
Jun 30 2024	n/a	n/a	US$450m
Mar 31 2024	n/a	n/a	US$399m
Dec 31 2023	US$16m	US$1m	US$379m
Sep 30 2023	n/a	n/a	US$583m
Jun 30 2023	n/a	n/a	US$677m
Mar 31 2023	n/a	n/a	US$789m
Dec 31 2022	US$15m	US$1m	US$1b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$21m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$3b
Jun 30 2021	n/a	n/a	US$3b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	US$15m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$845m
Jun 30 2020	n/a	n/a	US$362m
Mar 31 2020	n/a	n/a	US$321m
Dec 31 2019	US$6m	US$208k	US$824m
Sep 30 2019	n/a	n/a	US$755m
Jun 30 2019	n/a	n/a	US$853m
Mar 31 2019	n/a	n/a	US$896m
Dec 31 2018	US$301k	n/a	US$884m
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$290k	n/a	US$1b

Compensatie versus markt: De totale vergoeding ($USD 15.98M ) Adam } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 5.74M ).

Compensatie versus inkomsten: De vergoeding van Adam is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Adam Schechter (59 yo)

5yrs

Tenure

US$15,979,355

Compensatie

Mr. Adam H. Schechter serves as the President, CEO & Chairman of Laboratory Corporation of America Holdings. Mr. Adam serves as President & Chief Executive Officer at Labcorp Holdings Inc. since November...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Adam Schechter	President	5yrs	US$15.98m	0.10% MX$ 429.2m
Glenn Eisenberg	CFO & Executive VP	10.4yrs	US$4.96m	0.037% MX$ 153.6m
Mark Schroeder	Executive VP	1.5yrs	US$3.80m	0.0060% MX$ 24.7m
Brian Caveney	EVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer	1.5yrs	US$3.48m	0.033% MX$ 136.8m
Anita Graham	Executive VP & Chief Human Resources Officer	1.6yrs	US$2.56m	0.00035% MX$ 1.4m
Peter Wilkinson	Senior VP & Chief Accounting Officer	5.6yrs	geen gegevens	0.0025% MX$ 10.3m
Akinbolade Oyegunwa	Executive VP and Chief Information & Technology Officer	less than a year	geen gegevens	0.0032% MX$ 13.1m
Christin O'Donnell	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Sandra van der Vaart	Executive VP	5.8yrs	geen gegevens	0.0044% MX$ 18.0m
Amy Summy	Executive VP & Chief Marketing Officer	4.7yrs	geen gegevens	0.0047% MX$ 19.5m
Marcia Eisenberg	Enterprise Chief Scientific Officer & Senior VP	no data	geen gegevens	geen gegevens
Deborah Sesok-Pizzini	Chief Medical Officer	3.8yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LH * wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Adam Schechter	President	11.6yrs	US$15.98m	0.10% MX$ 429.2m
Peter Neupert	Independent Director	11.8yrs	US$357.87k	0.014% MX$ 58.6m
Kerrii Anderson	Independent Director	18.5yrs	US$340.73k	0.017% MX$ 68.8m
Garheng Kong	Lead Independent Director	10.9yrs	US$375.73k	0.014% MX$ 58.4m
Richelle Parham	Independent Director	8.8yrs	US$341.44k	0.010% MX$ 41.9m
D. Gilliland	Independent Director	10.6yrs	US$330.01k	0.010% MX$ 42.8m
Jeffrey Davis	Independent Director	4.9yrs	US$344.30k	0.0043% MX$ 17.8m
Paul Rothman	Independent Director	1.4yrs	US$208.42k	0.00087% MX$ 3.6m
Kathryn Wengel	Independent Director	3.7yrs	US$330.01k	0.0027% MX$ 11.2m
Kirsten Kliphouse	Independent Director	2.1yrs	US$330.01k	0.0016% MX$ 6.5m

9.7yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LH * wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.7 jaar).

Labcorp Holdings Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

CFO & Executive VP recently sold Mex$63m worth of stock

Insider recently sold Mex$54m worth of stock

Executive VP recently sold Mex$7.1m worth of stock

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Independent Director recently sold Mex$18m worth of stock

Recent updates

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

Third quarter 2024 earnings released: EPS: US$2.02 (vs US$2.12 in 3Q 2023)

Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024

Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test

Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024

Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million.

Upcoming dividend of US$0.72 per share

CFO & Executive VP recently sold Mex$63m worth of stock

Insider recently sold Mex$54m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).

Second quarter 2024 earnings released: EPS: US$2.44 (vs US$1.75 in 2Q 2023)

Labcorp Holdings Inc. Receives FDA De Novo Marketing Authorization for Pgdx Elio™ Plasma Focus Dx

Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024

Labcorp Declares Quarterly Cash Dividend, Payable on September 13, 2024

Labcorp Holdings Inc. to Report Q2, 2024 Results on Aug 01, 2024

Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials

Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio

Executive VP recently sold Mex$7.1m worth of stock

Dividend of US$0.72 announced

Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Labcorp Launches Weight Loss Management Testing Solutions

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024

Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia

Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024

Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company.

Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test

Labcorp Declares a Cash Dividend, Payable on December 12, 2023

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc.

Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023

Independent Director recently sold Mex$18m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc.

Upcoming dividend of US$0.72 per share at 1.3% yield

Second quarter 2023 earnings released: EPS: US$1.75 (vs US$3.89 in 2Q 2022)

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023

Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health.

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company.

Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023

Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board

Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire the outreach laboratory business and select assets of Providence Health & Services - Oregon.

Laboratory Corporation of America Holdings Appoints Mark S. Schroeder to Executive Vice President, President Diagnostics & Chief Operations Officer

First quarter 2023 earnings released: EPS: US$2.41 (vs US$5.28 in 1Q 2022)

Laboratory Corporation of America Holdings Provides Earnings Guidance for the Year 2023

Laboratory Corporation of America Holdings to Report Q4, 2022 Results on Feb 16, 2023

Labcorp Declares Cash Dividend on Common Stock, Payable on March 13, 2023

Labcorp Announces Executive Changes

Upcoming dividend of US$0.72 per share

Now 21% undervalued

Third quarter 2022 earnings released: EPS: US$3.91 (vs US$6.10 in 3Q 2021)

Laboratory Corporation of America Holdings Appoints Kirsten Kliphouse to Board of Directors

Labcorp Declares Quarterly Dividend, Payable on December 9, 2022

Laboratory Corporation of America Holdings (NYSE:LH) acquired Certain Outreach Laboratory Assets from Certain Outreach Laboratory Assets.

Laboratory Corporation of America Holdings to Report Q3, 2022 Results on Oct 27, 2022

Executive VP recently bought Mex$205k worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) acquired Clinical Outreach Laboratory Business and Select Related Assets of RWJBarnabas Health.

Upcoming dividend of US$0.72 per share